Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
Authors Yardley DA
Received 4 March 2019
Accepted for publication 4 March 2019
Published 3 May 2019 Volume 2019:11 Pages 189—190
Yardley DA. Breast Cancer Targets Therapy. 2015:7;293–301.
On page 300, Disclosure section, “The author reports no conflicts of interest in the work” has been updated since publication and should read “Dr Yardley reports nonfinancial support from Celgene pertaining to the work submitted. Dr Yardley reports grants to her institution, Sarah Cannon Research Institute, for studies on which she served as Principal Investigator, outside of the submitted work, from the following companies: Novartis, Janssen, Roche/Genentech, Bristol-Myers Squibb, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Medimmune, Medivation, Pfizer, Sanofi, Tesaro, Eisai, AbbVie, Astellas, Biomarin, Celldex, Clovis, Incyte, Merrimack, Imclone, Luitpold, Macrogenics, and Veridex. Dr Yardley reports that consulting fees were paid to her institution by the following companies for Dr Yardley’s services: Novartis, Roche/Genentech, Celgene, Lilly, Pfizer, Abraxis, Eisai, Spectrum, bioTheranostics, Celldex and OncoPlex Diagnostics. Dr Yardley reports non-financial support to her institution from Astellas, Sanofi, Lilly, and Celgene. The author reports no other conflicts of interest in this work”.
Read the original article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]